Larson Financial Group’s Summit Therapeutics SMMT Stock Holding History

Larson Financial Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.2K	Sell	1,730 -104	-6%	-$1.84K	﹤0.01%	1877
2026 Q1	$34.8K	Buy	1,834 +11	+0.6%	+$178	﹤0.01%	1554
2025 Q4	$31.9K	Buy	1,823 +108	+6%	+$2.03K	﹤0.01%	1456
2025 Q3	$35.4K	Buy	1,715 +68	+4%	+$1.65K	﹤0.01%	1316
2025 Q2	$35K	Hold	1,647	–	–	﹤0.01%	1219
2025 Q1	$31.8K	Hold	1,647	–	–	﹤0.01%	1192
2024 Q4	$29.4K	Hold	1,647	–	–	﹤0.01%	1078
2024 Q3	$36.1K	Hold	1,647	–	–	﹤0.01%	1005
2024 Q2	$12.8K	Hold	1,647	–	–	﹤0.01%	1190
2024 Q1	$6.82K	Hold	1,647	–	–	﹤0.01%	1132
2023 Q4	$4.3K	Hold	1,647	–	–	﹤0.01%	1219
2023 Q3	$3.08K	Hold	1,647	–	–	﹤0.01%	1268
2023 Q2	$4.13K	Hold	1,647	–	–	﹤0.01%	1141
2023 Q1	$2.88K	Hold	1,647	–	–	﹤0.01%	1189
2022 Q4	$7K	Buy	+1,647	New	+$3K	﹤0.01%	959
2019 Q4	–	Sell	-654	Closed	-$1K	–	656
2019 Q3	$1K	Hold	654	–	–	﹤0.01%	513
2019 Q2	$1K	Hold	654	–	–	﹤0.01%	464
2019 Q1	$1K	Buy	+654	New	+$1.07K	﹤0.01%	460

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Larson Financial Group's SMMT Position: Q2 2026 in Review

Larson Financial Group reduced its Summit Therapeutics (SMMT) stake by 5.7% in Q2 2026, selling an estimated $1.84K and leaving 1,730 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1877.

Larson Financial Group first reported a position in SMMT in Q1 2019 and has held it in 18 quarters since. The position peaked at $36.1K in Q3 2024. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Larson Financial Group held 1,730 shares of Summit Therapeutics worth $25.2K as of Q2 2026.
Larson Financial Group sold 104 Summit Therapeutics shares in Q2 2026, an estimated $1.84K.
Summit Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1877 holding.
Larson Financial Group first reported a position in Summit Therapeutics in Q1 2019 and has held it in 18 quarters since.
Larson Financial Group's Summit Therapeutics position peaked at $36.1K in Q3 2024.
243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.